Information Provided By:
Fly News Breaks for March 5, 2020
Mar 5, 2020 | 06:57 EDT
Citi analyst Joel Beatty initiated coverage of Ionis Pharmaceuticals with a Buy rating and $73 price target. Ionis has a "best-in-industry" antisense drug development platform with an "exceptionally deep" pipeline that should support upside to the current stock price, Beatty tells investors in a research note. The company has 16 clinical trial readouts over the next 12 months, and many of these agents are currently underappreciated, setting up favorable risk/reward into the readouts, adds the analsyt.
News For IONS From the Last 2 Days
There are no results for your query IONS